Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center)(Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center))

概要

基本信息

药物类型

治疗性疫苗、树突状细胞疫苗

别名

DC/MM Fusion Vaccine(Beth Israel Deaconess Medical Center)、Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions(Beth Israel Deaconess Medical Center)

靶点-

作用方式-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Beth Israel Deaconess Medical Center, Inc.

在研机构

Beth Israel Deaconess Medical Center, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) 相关的临床试验

NCT06799026

/ Not yet recruiting临床1期IIT

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

This research is being done to determine if the combination of the Dendritic Cell (DC)/ Multiple Myeloma (MM) fusion vaccine with elranatamab is safe and effective in treating Relapsed or Refractory Multiple Myeloma (MM).
The names of the study drugs and vaccine involved in this study are:
* DC/MM fusion vaccine (a personalized cancer vaccine in which harvested participant tumor cells are fused with harvested participant dendritic blood cells)
* Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (a type of growth factor)
* Elranatamab (a type of T-cell engager antibody)

开始日期2025-04-01

申办/合作机构

Beth Israel Deaconess Medical Center, Inc.

[+1]

100 项与 Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) 相关的临床结果

登录后查看更多信息

100 项与 Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) 相关的转化医学

登录后查看更多信息

100 项与 Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) 相关的专利（医药）

登录后查看更多信息

16

项与 Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) 相关的文献（医药）

2024-10-01·Clinical Cancer Research

Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401

作者: Holmberg, Leona ; Malek, Ehsan ; Chodon, Thinle ; Reese, Jane ; Pasquini, Marcelo C. ; Avigan, David ; Soiffer, Robert ; Ghiasuddin, Haider ; Callander, Natalie ; Geller, Nancy ; Dutt, Poorvi Somaiya ; Young, James W ; Dhakal, Binod ; Pasquini, Marcelo C ; Uhl, Lynne ; Rapoport, Aaron P. ; Logan, Brent ; Karagkouni, Dimitra ; Devine, Steve ; Vlachos, Ioannis S. ; Anderson, Kenneth ; O’Donnell, Lynn ; Rapoport, Aaron P ; Chung, David J ; McCarthy, Philip ; Rosenblatt, Jacalyn ; McKenna, David ; Vlachos, Ioannis S ; Cheloni, Giulia ; Wu, Juan ; Nooka, Ajay ; Johnson, Bryon ; Lazarus, Hillard M. ; O'Donnell, Lynn ; Stroopinsky, Dina ; Young, James W. ; Munshi, Nikhil ; Chung, David J. ; Efebera, Yvonne ; Shah, Nina ; Howard, Alan ; Waller, Edmund K. ; Hematti, Peiman ; Mendizabal, Adam ; Patel, Krina ; Waller, Edmund K ; Bisharat, Lina ; Lazarus, Hillard M

2023-12-01·Clinical Cancer Research

Personalized Medicine's Coming of Age: One Drug, One Patient

Article

作者: Kwak, Larry W ; Qazilbash, Muzaffar H

SummaryA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1 year posttransplant but was associated with a significant increase in circulating multiple myeloma–reactive lymphocytes indicative of tumor-specific immunity.See related article by Chung et al., p. 4784

2023-01-01·Theranostics

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.

Article

作者: Sun, Shuyang ; Hammock, Bruce D ; Liu, Aiqun ; Yang, Xiaomei ; Xie, Shenxia ; Mo, Fengzhen ; Ding, Ziqiang ; Huang, Xianing ; Li, Haixia ; Lu, Xiaoling ; Cheng, Qihong ; Gao, Li ; Wang, Xuan ; Shi, Wei ; Xu, Zhi Ping

Background: Chimeric antigen receptor (CAR) T-cell therapy is practical in treating cancers of hematopoietic origin, but of that in solid tumors compromises efficacy for the loss of the antigen recognized by the CAR. However, dendritic cell (DC)/tumor fusion vaccines present a spectrum of known or unknown tumor antigens to stimulate T cell expansion and enhanced T cell response. Developing a new strategy of enhanced nanobody-based CAR-T (Nb-CAR-T) cells antitumor activity by DC/tumor fusion vaccines stimulation would provide guidance for more effective CAR-T cell therapies. Methods: Considering the therapeutic potential of nanobody (Nb), we first screened EGFRvIII Nb, then constructed and verified the function of EGFRvIII Nb-CAR-T cells in vitro and in vivo. We further combined DC/tumor fusion vaccines to boost EGFRvIII Nb-CAR-T cells antitumor effect, which was evaluated in vitro Nb-CAR-T cell function and in the tumor-bearing xenograft mouse models. Results: We had for the first time successfully selected EGFRvIII Nb for the generation of the novel EGFRvIII Nb-CAR-T cells. Importantly, our results suggested that DC/tumor fusion vaccines stimulate Nb-CAR-T cells response not only in improving T cell proliferation, T cell activation, cytokine secretion and tumor-specific cytotoxicity in vitro, but also significantly reducing tumor burden, prolonging survival and improving Nb-CAR-T cells infiltration. Conclusions: We have innovatively shown that DC/tumor fusion vaccines significantly enhance the efficacy of Nb-CAR-T cells against solid tumors. This new strategy has provided a promising therapeutic platform for promoting the clinical treatment of CAR-T cells therapy.

100 项与 Dendritic Cell/Tumor Fusion Vaccine(Beth Israel Deaconess Medical Center) 相关的药物交易

登录后查看更多信息